Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +54.95%
#2 Pons Pons +47.77%
#3 TENDIES TENDIES +41.15%
#4 PondCoin PondCoin +34.57%
#5 StonkBroker StonkBroker +32.90%
#6 Magma Finance Magma Finance +32.11%
#7 Purr Purr +30.06%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.14%
#9 Ocean Protocol Ocean Protocol +26.58%
#10 SkyAI SkyAI +26.50%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
설정
언어
한국어
통화
USD
테마
SymBio Pharmaceuticals Limited SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited

4582
주식 순위 #28751
SymBio Pharmaceuticals Limited engages in the and development, manufacturing... SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
주가
$0.45018154
시가총액
$24.81M
변동 (1일)
1.47%
변동 (1년)
-56.57%
국가
JP
거래 SymBio Pharmaceuticals Limited (4582)

카테고리

Healthcare
SymBio Pharmaceuticals Limited (4582)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
SymBio Pharmaceuticals Limited의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
SymBio Pharmaceuticals Limited의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
10.24 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
14.89 -
US
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
- -
IT